<DOC>
	<DOCNO>NCT00618501</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . Imatinib mesylate may also stop growth cancer cell block enzymes necessary cancer cell growth . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . It yet know treatment regimen effective treat acute lymphoblastic leukemia . PURPOSE : This phase II trial study side effect give imatinib mesylate together combination chemotherapy without donor stem cell transplant see well work treat patient newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Imatinib Mesylate Combination Chemotherapy With Without Donor Stem Cell Transplant Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine clinical efficacy imatinib mesylate combination chemotherapy term complete response ( CR ) rate ( hematologic molecular ) , CR duration , overall survival patient newly diagnose Philadelphia chromosome-positive acute lymphoblastic leukemia . - To determine toxicity regimen patient . Secondary - To establish prognostic factor patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord age ( 64 less vs 65 ) . - Induction chemotherapy : Patients receive daunorubicin hydrochloride IV continuously 24 hour day 1-3 , vincristine IV day 1 8 , oral prednisolone day 1-14 . Treatment repeat 5 course absence disease progression unacceptable toxicity . - Imatinib mesylate administration : Patients also receive oral imatinib mesylate daily begin day 8 course 1 induction chemotherapy continue 2 year . - Consolidation chemotherapy : Patients receive daunorubicin hydrochloride IV continuously 24 hour day 1-2 , vincristine IV day 1 8 , oral prednisolone day 1-14 course 1 ; cytarabine IV 2 hour etoposide IV 3 hour day 1-4 course 2 4 ; methotrexate IV continuously 36 hour day 1-2 15-16 leucovorin calcium IV every 6 hour x 3 dos follow oral leucovorin calcium methotrexate level &lt; 0.05 micromol/L course 3 5 . Treatment continue absence disease progression unacceptable toxicity . Patients available HLA-matched sibling unrelated hematopoietic cell donor HLA-nonidentical familial hematopoietic cell donor proceed allogeneic hematopoietic stem cell transplantation ( HSCT ) . Patients without hematopoietic cell donor remain hematologic remission continue receive maintenance therapy oral imatinib mesylate . - Allogeneic HSCT : Patients undergo HSCT . - CNS prophylaxis : Patients receive six dos intrathecal ( IT ) methotrexate hydrocortisone begin first day chemotherapy course . Patients CNS disease diagnosis receive intensify CNS therapy comprise 10 dos IT methotrexate cranial irradiation bone marrow remission achieve . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute lymphoblastic leukemia ( ALL ) acute mixed lineage leukemia Newly diagnose disease Philadelphiachromosome positive ( Ph+ ) acute lymphoblastic leukemia Ph+ acute mixed lineage leukemia Positive result RTPCR BcrAbl transcript ( Ph+ ALL Philadelphiachromosome positive acute mixed lineage leukemia ) PATIENT CHARACTERISTICS : Bilirubin &lt; 2 mg/dL SGOT &lt; 3 time upper limit normal Creatinine &lt; 2.0 mg/dL Ejection fraction &gt; 45 % MUGA scan Not nurse Fertile patient must use effective contraception No known sensitivity study drug No severe medical condition , view investigator , prohibit participation study PRIOR CONCURRENT THERAPY : No investigational agent past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
</DOC>